Previous Article | Next Article ![]()
Journal of Clinical Microbiology, Jan 1997, 98-101, Vol 35, No. 1
JJ Ochnio, DW Scheifele, M Ho and LA Mitchell
Although detection of disease-induced hepatitis A virus (HAV)-specific
antibodies in saliva has been successfully utilized in a few
epidemiological studies, available assays fail to detect lower salivary
anti-HAV levels associated with vaccine-induced immunity. We present a new
capture enzyme immunoassay which employs a three-layer antibody recognition
system. Evaluation of paired saliva-serum specimens from 1,025
international travellers, 134 other volunteers, and 91 hepatitis A vaccine
recipients demonstrated 99.6% (95% confidence interval, 98.4 to 99.9)
specificity and 98.7% (95% confidence interval, 97.7 to 99.4) sensitivity
of this salivary assay in differentiating between immune and susceptible
individuals, compared with serum-based methods. We conclude that this assay
is sufficiently sensitive for reliable detection of both vaccine- and
infection-induced HAV-specific immunoglobulin G in saliva, even when
corresponding anti-HAV levels in serum are very low (< 1 IU/ml).
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
New, ultrasensitive enzyme immunoassay for detecting vaccine- and disease-induced hepatitis A virus-specific immunoglobulin G in saliva
Vaccine Evaluation Center, BC's Children's Hospital, Vancouver, Canada. jochnio@wpog.childhosp.bc.ca
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|